Navigation Links
Chemo Plus Synthetic Drug Shrunk Pancreatic Tumors
Date:3/25/2010

Research with mice might one day yield new therapies, study says

THURSDAY, March 25 (HealthDay News) -- When used with chemotherapy, an experimental synthetic drug called JP1201 was effective against human pancreatic cancer in mice, a new study found.

JP1201 mimics that action of a naturally occurring protein (Smac) that triggers cell death.

In this study, researchers gave JP1201 and the chemotherapy drug gemcitabine to mice with transplanted human pancreatic tumors.

"There was a 50 percent regression in tumor size during a two-week treatment of the mice," study senior author Dr. Rolf Brekken, an associate professor of surgery and pharmacology at the University of Texas Southwestern Medical Center in Dallas, said in a news release from the medical center.

The combination treatment also prolonged the life of the mice. The finding could lead to more effective therapies for pancreatic and possibly other cancers, the researchers said.

The study was published March 23 in the journal Cancer Research.

"This compound enhanced the efficacy of chemotherapy and improved survival in multiple animal models of pancreatic cancer. We now have multiple lines of evidence in animals showing that this combination is having a potent effect on pancreatic cancer, which is a devastating disease," Brekken said.

The research was supported by Joyant Pharmaceuticals, a Dallas-based company and UT Southwestern spinoff that's developing medical applications of compounds that mimic that action of the Smac protein.

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: UT Southwestern Medical Center, news release, March 23, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Chemo May Boost Survival After Lung Cancer Surgery
2. Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS
3. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
4. Researchers find new chemotherapy combination shows promise in endometrial cancer
5. BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
6. Are New Chemo Treatments Cost-Effective?
7. Older Colon Cancer Patients Less Likely to Get Chemo
8. Study evaluates costs and benefits of new chemotherapy drugs
9. Scientists identify microRNA as possible cause of chemotherapy resistance
10. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
11. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has announced ... Business Report" report to their offering. ... The report also analyses the market by the following ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
(Date:12/9/2016)... DIEGO , Dec. 9, 2016  Forge ... Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... targeting ,LpxC, for the treatment of bacterial infections ... has been recognized as an attractive antibacterial target ... a lack of suitable chemical starting points has ...
Breaking Medicine Technology: